Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide
Abstract
A 59-year old man with moderate and stable psoriasis through 15 years was admitted to our Department with inadequately controlled type 2 diabetes. Treatment was initiated with the glucagon-like peptide-1 receptor (GLP-1R) agonist liraglutide. The patient experienced marked improvement in his psoriasis immediately after the start of liraglutide treatment. Itching stopped within days, scaling was reduced and spots of normal skin emerged. After 3 months, psoriasis was still improving. Excellent glycaemic control and a weight loss of approximately 8 kg over 3 months were moreover obtained. The patient had previously been well controlled in his diabetes without improvement in psoriasis, and the effect of liraglutide on psoriasis started before weight loss occurred. We discuss the possibility of a direct anti-inflammatory effect of liraglutide in psoriasis as well as indirect effects through improvement in comorbidities such as overweight. Randomized clinical trials are needed to reveal whether GLP-1R agonists represent a new therapeutic option for psoriasis.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In type 2 diabetes patients, GLP-1 and liraglutide also improve clinical symptoms of psoriasis, a skin inflammatory disease, by downregulation of invariant natural killer T cells.
“In type 2 diabetes patients, GLP-1 and liraglutide also improve clinical symptoms of psoriasis, a skin inflammatory disease, by downregulation of invariant natural killer T cells [31, 113, 114].”
From Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control (2016) · cites this paper as [114]
Cites
1 retracted
Hattori, Y., Jojima, T., Tomizawa, A., Satoh, H., Hattori, S., Kasai, K., & Hayashi, T. (2010) · Diabetologia · doi:10.1007/s00125-010-1831-8 · Cited by 183 · see citing works
RetractedThe Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · see citing works
Risk of myocardial infarction in patients with psoriasis
Gelfand, J. M., Neimann, A. L., Shin, D. B., Wang, X., Margolis, D. J., & Troxel, A. B. (2006) · JAMA · doi:10.1001/jama.296.14.1735 · Cited by 1,899 · see citing works
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163 · see citing works
Nyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2004 · Cited by 680 · see citing works
Noyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A.-M., Zhou, Y.-Q., Riazi, A. M., Baggio, L. L., Henkelman, R. M., Husain, M., & Drucker, D. J. (2009) · Diabetes · doi:10.2337/db08-1193 · Cited by 575 · see citing works
Obesity, Waist Circumference, Weight Change, and the Risk of Psoriasis in Women
Setty, A. R. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.15.1670 · Cited by 485 · see citing works
Ahlehoff, O., Gislason, G., Charlot, M. G., Jørgensen, C. H., Lindhardsen, J., Olesen, J. B., Abildstrom, S. Z., Skov, L., Torp-Pedersen, C. T., & Hansen, P. R. (2010) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02310.x · Cited by 445 · see citing works
Self-citationKodera, R., Shikata, K., Kataoka, H. U., Takatsuka, T., Miyamoto, S., Sasaki, M., Kajitani, N., Nishishita, S., Sarai, K., Hirota, D., et al. (2011) · Diabetologia · doi:10.1007/s00125-010-2028-x · Cited by 394 · see citing works
Psoriasis and the Risk of Diabetes and Hypertension
Qureshi, A. A., Choi, H. K., Setty, A. R., & Curhan, G. C. (2009) · Archives of Dermatology · doi:10.1001/archdermatol.2009.48 · Cited by 249 · see citing works
Hogan, A. E., Tobin, A. M., Ahern, T., Corrigan, M. A., Gaoatswe, G., Jackson, R., O’Reilly, V., Lynch, L., Doherty, D. G., Moynagh, P. N., et al. (2011) · Diabetologia · doi:10.1007/s00125-011-2232-3 · Cited by 191 · see citing works
Hadjiyanni, I., Siminovitch, K. A., Danska, J. S., & Drucker, D. J. (2010) · Diabetologia · doi:10.1007/s00125-009-1643-x · Cited by 166 · see citing works
Chung, L. T. K., Hosaka, T., Yoshida, M., Harada, N., Sakaue, H., Sakai, T., & Nakaya, Y. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.10.015 · Cited by 160 · see citing works
Psoriasis Remission after Laparoscopic Roux-En-Y Gastric Bypass for Morbid Obesity
Higa, G., Szomstein, S., Soto, F. C., Brasecsco, O., Cohen, C., & Rosenthal, R. J. (2004) · Obesity Surgery · doi:10.1381/0960892041975569 · Cited by 102 · see citing works
Effect of gastric bypass surgery on the incretins
Laferrère, B. (2009) · Diabetes & Metabolism · doi:10.1016/s1262-3636(09)73458-5 · Cited by 89 · see citing works
Remission of Psoriasis after Open Gastric Bypass
Ettinger, J., Ázaro, E., de Souza, C. D. F., Filho, P. D. S., Mello, C., das Neves, M. C., do Amaral, P., & Fahel, E. (2005) · Obesity Surgery · doi:10.1381/096089206775221998 · Cited by 86 · see citing works
Gastric bypass surgery improves psoriasis
Hossler, E. W., Maroon, M. S., & Mowad, C. (2010) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2010.01.001 · Cited by 70 · see citing works
Glucagon-like peptide-1 protects mesenteric endothelium from injury during inflammation
Dozier, K. C., Cureton, E. L., Kwan, R. O., Curran, B., Sadjadi, J., & Victorino, G. P. (2009) · Peptides · doi:10.1016/j.peptides.2009.06.019 · Cited by 58 · see citing works
Glucagon-like peptide-1 receptor and proglucagon expression in mouse skin
List, J. F., He, H., & Habener, J. F. (2006) · Regulatory Peptides · doi:10.1016/j.regpep.2006.02.007 · Cited by 57 · see citing works
Glucagon-like peptide-1(1-37) inhibits chemokine-induced migration of human CD4-positive lymphocytes
Marx, N., Burgmaier, M., Heinz, P., Ostertag, M., Hausauer, A., Bach, H., Durst, R., Hombach, V., & Walcher, D. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0396-5 · Cited by 56 · see citing works
Sitagliptin, a Dipeptidyl Peptidase-IV Inhibitor, Improves Psoriasis
Nishioka, T., Shinohara, M., Tanimoto, N., Kumagai, C., & Hashimoto, K. (2011) · Dermatology · doi:10.1159/000333358 · Cited by 47 · see citing works
Incretin-Based Therapy and Type 2 Diabetes
Hare, K. J., & Knop, F. K. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00015-1 · Cited by 22 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control
Lee, Y.-S., & Jun, H.-S. (2016) · Mediators of Inflammation · doi:10.1155/2016/3094642 · Cited by 503 · see citing works
“In type 2 diabetes patients, GLP-1 and liraglutide also improve clinical symptoms of psoriasis, a skin inflammatory disease, by downregulation of invariant natural killer T cells [31, 113, 114].”
BackgroundPsoriasis and Cardiovascular Risk: A Comprehensive Review
Masson, W. M., Lobo, M., & Molinero, G. B. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01346-6 · Cited by 210 · see citing works
Seufert, J., & Gallwitz, B. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12251 · Cited by 156 · see citing works
Buysschaert, M., Baeck, M., Preumont, V., Marot, L., Hendrickx, E., Belle, A. V., & Dumoutier, L. (2014) · British Journal of Dermatology · doi:10.1111/bjd.12886 · Cited by 104 · see citing works
Ahern, T., Tobin, A., Corrigan, M., Hogan, A. E., Sweeney, C. M., Kirby, B., & O'Shea, D. B. (2012) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2012.04609.x · Cited by 91 · see citing works
Faurschou, A., Gyldenløve, M., Rohde, U., Thyssen, J. P., Zachariae, C. O. C., Skov, L., Knop, F. K., & Vilsbøll, T. (2014) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12629 · Cited by 90 · see citing works
Self-citationLin, L., Xu, X., Yunjie, Y., Ye, H., He, X., Chen, S., Chen, X., Shao, Z., & Chen, P. (2020) · Journal of Dermatological Treatment · doi:10.1080/09546634.2020.1826392 · Cited by 82 · see citing works
Xu, X., Lin, L., Chen, P., Yunjie, Y., Chen, S., Chen, X., & Shao, Z. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.03.002 · Cited by 76 · see citing works
Nagae, K., Uchi, H., Morino‐Koga, S., Tanaka, Y., Mari, O. D. A., & Furue, M. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.10.013 · Cited by 69 · see citing works
Hansen, N. W., & Sams, A. (2018) · Nutrients · doi:10.3390/nu10111590 · Cited by 65 · see citing works
The treatment of hidradenitis suppurativa with the glucagon‐like peptide‐1 agonist liraglutide
Jennings, L., Nestor, L. A., Molloy, O. E., Hughes, R., Moriarty, B., & Kirby, B. (2016) · British Journal of Dermatology · doi:10.1111/bjd.15233 · Cited by 65 · see citing works
Glucagon-Like Peptide 1 Receptor Agonists in Patients With Inflammatory Arthritis or Psoriasis
Karacabeyli, D., & Lacaille, D. V. (2023) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000001949 · Cited by 69 · see citing works
Psoriasis improvement after bariatric surgery
Romero‐Talamás, H., Aminian, A., Corcelles, R., Fernandez, A. P., Schauer, P. R., & Brethauer, S. A. (2014) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2014.03.025 · Cited by 57 · see citing works
Onoviran, O. F., Li, D., Smith, S. T., & Raji, M. A. (2019) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622319862691 · Cited by 59 · see citing works
Andersen, D. B., Grunddal, K. V., Pedersen, J., Kuhre, R. E., Lund, M. L., Holst, J. J., & Ørskov, C. (2021) · Endocrinology · doi:10.1210/endocr/bqaa246 · Cited by 54 · see citing works
Petković-Dabić, J., Binić, I., Carić, B., Božić, L., Umičević-Šipka, S., Bednarčuk, N., Dabić, S., Šitum, M., Popović‐Pejičić, S., Stojiljković, M. P., et al. (2025) · Biomolecules · doi:10.3390/biom15010046 · Cited by 51 · see citing works
Chang, G., Chen, B., & Zhang, L. (2021) · Journal of Dermatological Treatment · doi:10.1080/09546634.2021.1882658 · Cited by 46 · see citing works
Induced Human Regulatory T Cells Express the Glucagon-like Peptide-1 Receptor
Rode, A. K. O., Buus, T. B., Mraz, V., Al-Jaberi, F. A. H., Lopez, D. V., Ford, S. L., Hennen, S., Eliasen, I. P., Klewe, I. V., Gharehdaghi, L., et al. (2022) · Cells · doi:10.3390/cells11162587 · Cited by 45 · see citing works
Self-citationEffect of glucagon-like peptide-1 receptor agonists in patients with psoriasis
Al-Badri, M. R., & Azar, S. T. (2014) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018814543483 · Cited by 44 · see citing works
The effects of GLP‐1RA on inflammatory skin diseases: A comprehensive review
Paschou, I. A., Sali, E., Paschou, S. Α., Ψαλτοπούλου, Θ., Nicolaidou, E., & Stratigos, A. J. (2025) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.20694 · Cited by 50 · see citing works
A Closer Look at the Dermatological Profile of GLP-1 Agonists
Persson, C., Eaton, A. C., & MAYROVITZ, H. N. (2025) · Diseases · doi:10.3390/diseases13050127 · Cited by 43 · see citing works
Shao, S., Zhang, X., Xu, Q., Pan, R., & Chen, Y. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108270 · Cited by 42 · see citing works
GLP-1 receptor agonist impairs keratinocytes inflammatory signals by activating AMPK
Yang, J. X., Wang, Z., & Zhang, X. (2019) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2019.01.014 · Cited by 41 · see citing works
GLP-1: benefits beyond pancreas
Muscogiuri, G., Cignarelli, A., Giorgino, F., Prodram, F., Santi, D., Tirabassi, G., Balercia, G., Modica, R., Faggiano, A., & Colao, A. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0137-y · Cited by 41 · see citing works
Glycemic Control in the Treatment of Psoriasis
Ip, W., & Kirchhof, M. G. (2017) · Dermatology · doi:10.1159/000472149 · Cited by 40 · see citing works
The obesity–inflammation axis in psoriatic disease: mechanisms and therapeutic strategies
Haberman, R. H., Ogdie, A., Merola, J. F., Scher, J. U., & Eder, L. (2025) · Nature Reviews Rheumatology · doi:10.1038/s41584-025-01326-6 · Cited by 43 · see citing works
Nassar, M., Nassar, O., Abosheaishaa, H. M., & Misra, A. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02466-4 · Cited by 34 · see citing works
Hansen, N. W., Hansen, A. J., & Sams, A. G. (2017) · IUBMB Life · doi:10.1002/iub.1610 · Cited by 34 · see citing works
Chen, P., Lin, L., Xu, X., Zhang, Z., Cai, W., Shao, Z., Chen, S., Chen, X., & Weng, Q. (2019) · Journal of Dermatological Treatment · doi:10.1080/09546634.2019.1708853 · Cited by 29 · see citing works
Liraglutide in combination with acitretin for severe recalcitrant psoriasis
Reid, C., Tobin, A., Ahern, T., O'Shea, D. B., & Kirby, B. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12380 · Cited by 24 · see citing works
The role of incretins and incretin-based drugs in autoimmune diseases
Radbakhsh, S., Atkin, S. L., Simental‐Mendía, L. E., & Sahebkar, A. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107845 · Cited by 24 · see citing works
Pantazopoulos, D., Gouveri, E., Papi, M., Papazoglou, D., & Παπάνας, Ν. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03257-w · Cited by 20 · see citing works
Effects of Hypolipidemic Drugs on Psoriasis
Matwiejuk, M., Myśliwiec, H., Jakubowicz-Zalewska, O., Chabowski, A., & Flisiak, I. (2023) · Metabolites · doi:10.3390/metabo13040493 · Cited by 20 · see citing works
Impact of GLP-1 Receptor Agonists on Psoriasis and Cardiovascular Comorbidities: A Narrative Review
Haran, K., Johnson, C., Smith, P. L., Venable, Z., Kranyak, A. C., Bhutani, T., Jeon, C., & Liao, W. J. (2024) · Psoriasis Targets and Therapy · doi:10.2147/ptt.s485061 · Cited by 19 · see citing works
Cedirian, S., Donati, M., Rapparini, L., Pampaloni, F., Plaça, M. L., Sgarzani, R., Negosanti, L., Raschi, E., & Starace, M. V. R. (2025) · Dermatology and Therapy · doi:10.1007/s13555-025-01537-5 · Cited by 22 · see citing works
Eraky, S. M., Ramadan, N. M., & El‐Magd, N. F. A. (2021) · Cell Biochemistry and Function · doi:10.1002/cbf.3678 · Cited by 18 · see citing works
Thin, L. W. Y., & Teh, W. L. (2025) · Biomedicines · doi:10.3390/biomedicines13051128 · Cited by 17 · see citing works
Scala, E., Mercurio, L., Albanesi, C., & Madonna, S. (2024) · Life · doi:10.3390/life14060733 · Cited by 15 · see citing works
Atiquzzaman, N. T., Razdolsky, N., & Parmar, M. S. (2025) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-025-03898-4 · Cited by 14 · see citing works
Unconventional treatment options in psoriasis: A review
Neema, S., Sandhu, S., Gupta, A., Jagadeesan, S., & Vasudevan, B. (2021) · Indian Journal of Dermatology Venereology and Leprology · doi:10.25259/ijdvl_22_2021 · Cited by 15 · see citing works
Lynch, M., Ahern, T., Timoney, I., Sweeney, C. M., Kelly, G., Hughes, R., Tobin, A., O'Shea, D. B., & Kirby, B. (2016) · Trials · doi:10.1186/s13063-016-1157-z · Cited by 14 · see citing works
Skin changes and manifestations associated with the treatment of obesity
Rosen, J. D., Darwin, E., Tuchayi, S. M., Garibyan, L., & Yosipovitch, G. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.10.081 · Cited by 13 · see citing works
Molecular mechanisms and drug therapy of metabolism disorders in psoriasis
Liang, Y., Wang, Y., Peng, A., Li, J., & Zhang, K. (2024) · Journal of Dermatological Treatment · doi:10.1080/09546634.2024.2375580 · Cited by 11 · see citing works
Glucagon‐like peptide‐1 agonists for treatment of hidradenitis suppurativa
Emtestam, L., & Sartorius, K. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15742 · Cited by 11 · see citing works
Šabović, E. K. M., Zorko, M. S., & Janić, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126648 · Cited by 9 · see citing works
Clinical effects of antidiabetic drugs on psoriasis: The perspective of evidence-based medicine
Zhang, M., Zheng, B.-Y., Chen, H., & Chien, C.-W. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i8.1141 · Cited by 8 · see citing works
Ciancìo, G., Maranini, B., Sandri, G., Amati, G., Bortoluzzi, A., Silvagni, E., Govoni, M., & Giuggioli, D. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1744308 · Cited by 7 · see citing works
Psoriasis and Obesity: A Review of the Current Literature
Orloff, J. N., Kaminetsky, J. R., & Aziz, M. D. (2018) · SKIN The Journal of Cutaneous Medicine · doi:10.25251/skin.2.6.4 · Cited by 6 · see citing works
Ho, M. J., Liew, C. F., Tan, N. A. M. R., Morita, A., & Oon, H. H. B. (2026) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2026.2665732 · Cited by 5 · see citing works
GLP-1RAs in patients with psoriasis
Paschou, I. A., Sali, E., Paschou, S. Α., Ψαλτοπούλου, Θ., Nicolaidou, E., & Stratigos, A. J. (2025) · HORMONES · doi:10.1007/s42000-025-00635-5 · Cited by 5 · see citing works
Efficacy of glucagon-like peptide 1 analogues in psoriasis: A cohort study
Bar, D., Pavlotsky, F., Baum, S., & Barzilai, A. (2026) · JAAD International · doi:10.1016/j.jdin.2026.04.004 · Cited by 4 · see citing works
Marani, A., Neri, E., Morea, E., Bertolla, D., Gualdi, G., Borghi, A., Conti, A., & Amerio, P. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15135126 · Cited by 2 · see citing works
Hadi, N. R., Al-Dhalimi, A., & al Harchan, N. (2016) · American Journal of BioMedicine · doi:10.18081/2333-5106/016-10/410-420 · Cited by 2 · see citing works
Ramakrishnan, S., Khan, M. Y., Ramakrishnan, A., Gopal, S., & Warrier, R. S. (2020) · Journal of Endocrinological Science · doi:10.29245/2767-5157/2020/1.1106 · Cited by 2 · see citing works
Lila, A. M., Korotaeva, T. V., Паневин, Т. С., & Zotkin, E. G. (2026) · Modern Rheumatology Journal · doi:10.14412/1996-7012-2026-3-84-90 · Cited by 1 · see citing works
Effects of hypolipemic drugs on psoriasis v1Preprint
Matwiejuk, M., Mysliwiec, H., Jakubowicz-Zalewska, O., Chabowski, A., & Flisiak, I. (2023) · doi:10.17504/protocols.io.261ge311wl47/v1 · Cited by 1 · see citing works
Preumont, V., Baeck, M., Marot, L., Dumoutier, L., & Buysschaert, M. (2014) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(14)70729-1
Teixeira, P. C. C. (2015) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/x485-j713
Saha, B. B., Thu, K., & Wijayanta, A. T. (2018) · Evergreen · doi:10.5109/1957499
Glucagon Like Peptide-1: More than Glucose Control and Weight ReductionPreprint
Chen, Y., Shao, S., Zhang, X., Xu, Q., & Pan, R. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4161722
Drug Repurposing: Harnessing the Therapeutics from Antidiabetic Molecules
Bhatta, A., Mahale, P., Baral, H., Yuvaraj, D. K., & Kaundal, R. K. (2026) · Springer eBooks · doi:10.1007/978-981-95-4522-3_3
Adapting Glucagon-Like Peptide-1 Receptor Agonists for Innovative Psoriasis Therapy
Tanquilut, E., Dumke, M., Parga, A., Suhling, M., Hunt, J., Bae, K., Kong, Y., & Frasier, K. M. (2026) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/12034754261428062
Incretins beyond weight and hyperglycemia management: a consensus statement by AASD
Shaltout, I., Hegazy, M., Meligi, A. A. H. E., Abdelghaffar, S., Wifi, M.-N. A., Saleh, A. A., Hammad, H., Abouzeid, A. A. E. K., Fahmy, E. M., Maghraby, G. G., et al. (2026) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-026-00689-w
Long, X., Qiu, Y., Lin, Z., Liu, Y., Fang, J., Wang, Y., Li, Y., Sun, Y., Zeng, S., & Huang, K. (2026) · Dermatologic Therapy · doi:10.1155/dth/9612721
Segedi, A., Vesković, D., Nišavić, M., & Levakov, O. (2026) · Medicinski pregled · doi:10.2298/mpns2608189s
- Authors
- Faurschou, A., Knop, F. K., Thyssen, J. P., Zachariae, C., Skov, L., & Vilsbøll, T.
- Affiliations
- University of Copenhagen (DK)
- Corresponding author
- Faurschou, A.
- Venue
- Acta Diabetologica
- Published
- 2011-12-13
- Volume
- 51
- Issue
- 1
- Pages
- 147-150
- ISSN
- 0940-5429 (ISSN-L)
- 1432-5233
- OpenAlex
- W2076276438
- Cited by
- 65
- References
- 22
- Citations by year
- 2026: 10 · 2025: 9 · 2024: 4 · 2023: 3 · 2022: 4 · 2021: 5 · 2020: 4 · 2019: 5 · 2018: 4 · 2017: 3 · 2016: 4 · 2015: 1 · 2014: 6 · 2013: 2 · 2012: 1
- FWCI
- 1.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Acta Diabetologica (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Novo Nordisk Fonden (NNF12OC1015904)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Dermatology › Skin Diseases and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- psoriasis, liraglutide, GLP-1 receptor agonists, type 2 diabetes, anti-inflammatory activity, weight loss, comorbidities, glycemic control, psoriasis treatment
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Diabetes Mellitus, Type 2, Humans, Male, Middle Aged, Psoriasis, Treatment Outcome, Receptors, Glucagon, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
